FREE SHIPPING over $40
OVER 9000 FIVE-STAR REVIEWS
5% OFF ALL SUBSCRIPTIONS
100% HAPPINESS GUARANTEE
Analyze Diet
0
Home / Equine Research Bank / Virus Res / Curing of HeLa cells persistently infected with equine arter...
Virus research2010; 150(1-2); 138-142; doi: 10.1016/j.virusres.2010.02.013

Curing of HeLa cells persistently infected with equine arteritis virus by a peptide-conjugated morpholino oligomer.

Abstract: A significant consequence of equine arteritis virus (EAV) infection of horses is persistence of the virus in a variable percentage of infected stallions. We recently established an in vitro model of EAV persistence in cell culture for the purpose of furthering our understanding of EAV biology in general and viral persistence in the stallion in particular. In this study we investigated whether persistently infected HeLa cells could be cured of EAV infection by treatment with an antisense peptide-conjugated phosphorodiamidate morpholino oligomer (PPMO) designed to target the 5'-terminal region of the EAV genome. We found that persistently infected HeLa cells passaged three times in the presence of 5-10 microM EAV-specific PPMO produced no detectable virus. The PPMO-cured HeLa cells were free of infectious virus, viral antigen and EAV RNA as measured by plaque assay, indirect immunofluorescence assay and RT-PCR, respectively. Furthermore, when re-challenged with EAV at several passages after discontinuation of PPMO treatments, PPMO-cured HeLa cells were found to be refractory to re-infection and to the re-establishment of viral persistence. While these findings demonstrate that PPMO can be used to eliminate persistent EAV infection in cell culture, the efficacy of PPMO against EAV in vivo remains to be addressed.
(c) 2010 Elsevier B.V. All rights reserved.
Get Full Text
Publication Date: 2010-03-03 PubMed ID: 20206215PubMed Central: PMC7114391DOI: 10.1016/j.virusres.2010.02.013Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
LinkedInCopy
  • Journal Article
  • Research Support
  • Non-U.S. Gov't

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

The study explores the possibility of eliminating persistent equine arteritis virus (EAV) infection in HeLa cells using a peptide-conjugated morpholino oligomer (PPMO) targeting the virus’s genome. The research findings were promising, with no detectable levels of EAV after treatment. However, in vivo effectiveness remains untested.

Understanding the Research Problems

  • The study is centered on EAV, a virus infecting horses that becomes persistent in a fluctuating percentage of infected stallions. The persistence of EAV poses challenges for the health of horses.
  • Scientists created an in vitro model in recent studies to investigate the EAV’s biology and its persistence in stallions. However, this study further explores the possibility of curing EAV persistence using a unique approach – applying an antisense peptide-conjugated morpholino oligomer (PPMO).

Study Methodology and Findings

  • The researchers used a specific PPMO designed to target the 5′-terminal region of the EAV genome. This antisense molecule was applied to HeLa cells persistently infected with EAV.
  • Subsequent to the application of EAV-specific PPMO (ranging between 5-10 microM) and passing the HeLa cells through three passages, no detectable virus was found.
  • The tests confirmed that PPMO-treated HeLa cells were devoid of infectious virus, viral antigen and EAV RNA. This was determined by the plaque assay, indirect immunofluorescence assay, and RT-PC
  • Moreover, the study found that these “cured” HeLa cells remained resistant to the EAV when re-challenged with the virus, even after several passages sans the PPMO treatments.
  • Overall, the findings confirm the efficacy of PPMO in eliminating persistent EAV infection in an in vitro cell culture environment.

Pending Research Directions

  • Although the findings from this in vitro study are promising, the effectiveness of PPMO against EAV in a real-world, in vivo setting remains unaddressed. Future research needs to take this direction to confirm if PPMO treatments could indeed eliminate persistent EAV infections in stallions.

Cite This Article

APA
Zhang J, Stein DA, Timoney PJ, Balasuriya UB. (2010). Curing of HeLa cells persistently infected with equine arteritis virus by a peptide-conjugated morpholino oligomer. Virus Res, 150(1-2), 138-142. https://doi.org/10.1016/j.virusres.2010.02.013

Publication

Virus research
ISSN: 1872-7492
NlmUniqueID: 8410979
Country: Netherlands
Language: English
Volume: 150
Issue: 1-2
Pages: 138-142

Researcher Affiliations

Zhang, Jianqiang
  • Department of Veterinary Science, Maxwell H. Gluck Equine Research Center, University of Kentucky, Lexington, KY 40546, USA.
Stein, David A
    Timoney, Peter J
      Balasuriya, Udeni B R

        MeSH Terms

        • Animals
        • Antiviral Agents / chemistry
        • Antiviral Agents / pharmacology
        • Equartevirus / drug effects
        • Equartevirus / growth & development
        • HeLa Cells
        • Horses
        • Humans
        • Morpholines / chemistry
        • Morpholines / pharmacology
        • Morpholinos
        • Oligonucleotides, Antisense / chemistry
        • Oligonucleotides, Antisense / pharmacology
        • Peptides / chemistry
        • Peptides / pharmacology

        References

        This article includes 36 references
        1. Abes S, Moulton H.M, Clair P, Prevot P, Youngblood D.S, Wu R.P, Iversen P.L, Lebleu B. Vectorization of morpholino oligomers by the (R-Ahx-R)4 peptide allows efficient splicing correction in the absence of endosomolytic agents.. J. Control. Release 2006;116(3):304–313.
          pubmed: 17097177
        2. Balasuriya U.B, Hedges J.F, Nadler S.A, McCollum W.H, Timoney P.J, MacLachlan N.J. Genetic stability of equine arteritis virus during horizontal and vertical transmission in an outbreak of equine viral arteritis.. J. Gen. Virol. 1999;80(Pt 8):1949–1958.
          pubmed: 10466790
        3. Balasuriya U.B, Hedges J.F, Smalley V.L, Navarrette A, McCollum W.H, Timoney P.J, Snijder E.J, MacLachlan N.J. Genetic characterization of equine arteritis virus during persistent infection of stallions.. J. Gen. Virol. 2004;85(Pt 2):379–390.
          pubmed: 14769895
        4. Balasuriya U.B, Leutenegger C.M, Topol J.B, McCollum W.H, Timoney P.J, MacLachlan N.J. Detection of equine arteritis virus by real-time TaqMan reverse transcription-PCR assay.. J. Virol. Methods 2002;101(1–2):21–28.
          pubmed: 11849680
        5. Burrer R, Neuman B.W, Ting J.P, Stein D.A, Moulton H.M, Iversen P.L, Kuhn P, Buchmeier M.J. Antiviral effects of antisense morpholino oligomers in murine coronavirus infection models.. J. Virol. 2007;81(11):5637–5648.
          pmc: PMC1900280pubmed: 17344287
        6. Cavanagh D. Nidovirales: a new order comprising Coronaviridae and Arteriviridae.. Arch. Virol. 1997;142(3):629–633.
          pubmed: 9349308
        7. Deas T.S, Binduga-Gajewska I, Tilgner M, Ren P, Stein D.A, Moulton H.M, Iversen P.L, Kauffman E.B, Kramer L.D, Shi P.Y. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication.. J. Virol. 2005;79(8):4599–4609.
          pmc: PMC1069577pubmed: 15795246
        8. Gilbert S.A, Timoney P.J, McCollum W.H, Deregt D. Detection of equine arteritis virus in the semen of carrier stallions by using a sensitive nested PCR assay.. J. Clin. Microbiol. 1997;35(8):2181–2183.
          pmc: PMC229933pubmed: 9230412
        9. Han X, Fan S, Patel D, Zhang Y.J. Enhanced inhibition of porcine reproductive and respiratory syndrome virus replication by combination of morpholino oligomers.. Antiviral Res. 2009;82(1):59–66.
          pmc: PMC7114178pubmed: 19428596
        10. Hedges J.F, Balasuriya U.B, Timoney P.J, McCollum W.H, MacLachlan N.J. Genetic divergence with emergence of novel phenotypic variants of equine arteritis virus during persistent infection of stallions.. J. Virol. 1999;73(5):3672–3681.
          pmc: PMC104142pubmed: 10196259
        11. Holyoak G.R, Little T.V, McCollam W.H, Timoney P.J. Relationship between onset of puberty and establishment of persistent infection with equine arteritis virus in the experimentally infected colt.. J. Comp. Pathol. 1993;109(1):29–46.
          pmc: PMC7130259pubmed: 8408779
        12. Little T.V, Holyoak G.R, McCollum W.H, Timoney P.J. Output of equine arteritis virus from persistently infected stallion is testosterone dependent.. Proceedings of the 6th International Conference of Equine Infectious Diseases Cambridge, UK; 1991. pp. 225–229.
        13. Lu Z, Branscum A.J, Shuck K.M, Zhang J, Dubovi E.J, Timoney P.J, Balasuriya U.B. Comparison of two real-time reverse transcription polymerase chain reaction assays for the detection of Equine arteritis virus nucleic acid in equine semen and tissue culture fluid.. J. Vet. Diagn. Invest. 2008;20(2):147–155.
          pubmed: 18319426
        14. MacLachlan N.J, Balasuriya U.B, Hedges J.F, Schweidler T.M, McCollum W.H, Timoney P.J, Hullinger P.J, Patton J.F. Serologic response of horses to the structural proteins of equine arteritis virus.. J. Vet. Diagn. Invest. 1998;10(3):229–236.
          pubmed: 9683071
        15. McCollum W.H, Doll E.R, Wilson J.C, Cheatham J. Isolation and propagation of equine arteritis virus in monolayer cell cultures of rabbit kidney.. Cornell Vet. 1962;52:452–458.
          pubmed: 14007366
        16. McCollum W.H, Little T.V, Timoney P.J, Swerczek T.W. Resistance of castrated male horses to attempted establishment of the carrier state with equine arteritis virus.. J. Comp. Pathol. 1994;111(4):383–388.
          pubmed: 7884055
        17. Moulton H.M, Nelson M.H, Hatlevig S.A, Reddy M.T, Iversen P.L. Cellular uptake of antisense morpholino oligomers conjugated to arginine-rich peptides.. Bioconjug. Chem. 2004;15(2):290–299.
          pubmed: 15025524
        18. Neuman B.W, Stein D.A, Kroeker A.D, Churchill M.J, Kim A.M, Kuhn P, Dawson P, Moulton H.M, Bestwick R.K, Iversen P.L, Buchmeier M.J. Inhibition, escape, and attenuated growth of severe acute respiratory syndrome coronavirus treated with antisense morpholino oligomers.. J. Virol. 2005;79(15):9665–9676.
          pmc: PMC1181598pubmed: 16014928
        19. Neuman B.W, Stein D.A, Kroeker A.D, Paulino A.D, Moulton H.M, Iversen P.L, Buchmeier M.J. Antisense morpholino-oligomers directed against the 5′ end of the genome inhibit coronavirus proliferation and growth.. J. Virol. 2004;78(11):5891–5899.
          pmc: PMC415795pubmed: 15140987
        20. Patel D, Opriessnig T, Stein D.A, Halbur P.G, Meng X.J, Iversen P.L, Zhang Y.J. Peptide-conjugated morpholino oligomers inhibit porcine reproductive and respiratory syndrome virus replication.. Antiviral Res. 2008;77(2):95–107.
          pmc: PMC7114306pubmed: 17959259
        21. Patel D, Stein D.A, Zhang Y.J. Morpholino oligomer-mediated protection of porcine pulmonary alveolar macrophages from arterivirus-induced cell death.. Antivir. Ther. 2009;14(7):899–909.
          pubmed: 19918094
        22. Snijder E.J, Meulenberg J.J. The molecular biology of arteriviruses.. J. Gen. Virol. 1998;79(Pt 5):961–979.
          pubmed: 9603311
        23. Snijder E.J, Spaan W.J. Arteriviruses.. Fields Virology 5th ed. Lippincott Williams & Wilkins; Philadelphia: 2006. pp. 1337–1355.
        24. Snijder E.J, van Tol H, Pedersen K.W, Raamsman M.J, de Vries A.A. Identification of a novel structural protein of arteriviruses.. J. Virol. 1999;73(8):6335–6345.
          pmc: PMC112712pubmed: 10400725
        25. Stein D, Foster E, Huang S.B, Weller D, Summerton J. A specificity comparison of four antisense types: morpholino, 2′-O-methyl RNA, DNA, and phosphorothioate DNA.. Antisense Nucleic Acid Drug Dev. 1997;7(3):151–157.
          pubmed: 9212905
        26. Stein D.A. Inhibition of RNA virus infections with peptide-conjugated morpholino oligomers.. Curr. Pharm. Des. 2008;14(25):2619–2634.
          pubmed: 18991679
        27. Summerton J. Morpholino antisense oligomers: the case for an RNase H-independent structural type.. Biochim. Biophys. Acta. 1999;1489(1):141–158.
          pubmed: 10807004
        28. Summerton J, Weller D. Morpholino antisense oligomers: design, preparation, and properties.. Antisense Nucleic Acid Drug Dev. 1997;7(3):187–195.
          pubmed: 9212909
        29. Timoney P.J. Equine viral arteritis: epidemiology and control.. J. Equine Vet. Sci. 1988;8:54–59.
        30. Timoney P.J, McCollum W.H. Equine viral arteritis.. Vet. Clin. North Am. Equine Pract. 1993;9(2):295–309.
          pmc: PMC7134676pubmed: 8395325
        31. Timoney P.J, McCollum W.H, Vickers M.L. The carrier stallion as a reservoir of equine arteritis virus.. Equine Dis. Q. 1997;6(1):2.
        32. van den Born E, Stein D.A, Iversen P.L, Snijder E.J. Antiviral activity of morpholino oligomers designed to block various aspects of Equine arteritis virus amplification in cell culture.. J. Gen. Virol. 2005;86(Pt 11):3081–3090.
          pubmed: 16227231
        33. Wagner H.M, Balasuriya U.B, James MacLachlan N. The serologic response of horses to equine arteritis virus as determined by competitive enzyme-linked immunosorbent assays (c-ELISAs) to structural and non-structural viral proteins.. Comp. Immunol. Microbiol. Infect. Dis. 2003;26(4):251–260.
          pubmed: 12676125
        34. Zhang J, Timoney P.J, Maclachlan N.J, Balasuriya U.B. Identification of an additional neutralization determinant of equine arteritis virus.. Virus Res. 2008;138(1–2):150–153.
          pubmed: 18851997
        35. Zhang J, Timoney P.J, MacLachlan N.J, McCollum W.H, Balasuriya U.B. Persistent equine arteritis virus infection in HeLa cells.. J. Virol. 2008;82(17):8456–8464.
          pmc: PMC2519626pubmed: 18579588
        36. Zhang Y.J, Stein D.A, Fan S.M, Wang K.Y, Kroeker A.D, Meng X.J, Iversen P.L, Matson D.O. Suppression of porcine reproductive and respiratory syndrome virus replication by morpholino antisense oligomers.. Vet. Microbiol. 2006;117(2–4):117–129.
          pmc: PMC7117520pubmed: 16839712

        Citations

        This article has been cited 3 times.
        1. Sakai A, Singh G, Khoshbakht M, Bittner S, Löhr CV, Diaz-Tapia R, Warang P, White K, Luo LL, Tolbert B, Blanco M, Chow A, Guttman M, Li C, Bao Y, Ho J, Maurer-Stroh S, Chatterjee A, Chanda S, García-Sastre A, Schotsaert M, Teijaro JR, Moulton HM, Stein DA. Inhibition of SARS-CoV-2 growth in the lungs of mice by a peptide-conjugated morpholino oligomer targeting viral RNA. Mol Ther Nucleic Acids 2024 Dec 10;35(4):102331.
          doi: 10.1016/j.omtn.2024.102331pubmed: 39376996google scholar: lookup
        2. Nan Y, Zhang YJ. Antisense Phosphorodiamidate Morpholino Oligomers as Novel Antiviral Compounds. Front Microbiol 2018;9:750.
          doi: 10.3389/fmicb.2018.00750pubmed: 29731743google scholar: lookup
        3. Balasuriya UB, Go YY, MacLachlan NJ. Equine arteritis virus. Vet Microbiol 2013 Nov 29;167(1-2):93-122.
          doi: 10.1016/j.vetmic.2013.06.015pubmed: 23891306google scholar: lookup
        Subscribe to our newsletter
        Join 99,001 horse owners like you who receive our email updates on horse health and nutrition.